A Phase 1 interventional study of Linagliptin/Metformin (standard batch) and Linagliptin/Metformin (side batch) in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 21 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-27.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of the current study is to investigate the relative bioavailability of two different batches of a 2.5 mg linagliptin / 1000 mg metformin fixed dose combination tablet (FDC).
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Inability to comply with dietary regimen of trial site
For female subjects of only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fixed dose combination tablet
Drug: Linagliptin/Metformin (standard batch)
Fixed dose combination tablet
Drug: Linagliptin/Metformin (side batch)
Drug pages: LinagliptinStudies of LinagliptinLinagliptin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Fixed dose combination tablet
Drug pages: LinagliptinStudies of LinagliptinLinagliptin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Fixed dose combination tablet
Linagliptin: Maximum Measured Concentration (Cmax)
Geometric mean of Cmax of Linagliptin
Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72)
Geometric mean of AUC0-72 of Linagliptin
Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Metformin: Cmax
Geometric Mean of Cmax of Metformin
Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Metformin: AUC0-tz
Geometric Mean of AUC0-tz of Metformin
Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Linagliptin: AUC0-infinity
Geometric mean of AUC0-infinity of Linagliptin
Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Linagliptin: Percentage of AUCtz-∞ Obtained by Extrapolation
Geometric Mean of percentage of AUCtz-∞ of linagliptin, where percentage is the unit of measurement.
Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Linagliptin: Time to Maximum Measured Concentration of the Analyte in Plasma (Tmax)
Median of the t_max of linagliptin
Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Linagliptin: λz (Terminal Elimination Rate Constant in Plasma)
Geometric mean of the λ_z of linagliptin
Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2
t1/2 (Terminal Half-life of the Analyte in Plasma)
Geometric mean of the t1/2 of linagliptin
Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Linagliptin: MRTpo (Mean Residence Time of the Analyte in the Body After Peroral Administration)
Geometric mean of the MRTpo of linagliptin
Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Linagliptin: Apparent Clearance of the Analyte in Plasma After Extravascular Administration (CL/F)
Geometric mean of the CL/F of linagliptin
Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Linagliptin: Apparent Volume of Distribution During the Terminal Phase Following an Extravascular Dose (Vz/F)
Geometric mean of the Vz/F of linagliptin
Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Metformin: AUC0-infinity
Geometric Mean of AUC0-infinity of Metformin
Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Metformin: Percentage of AUCtz-∞ Obtained by Extrapolation
Geometric Mean of the percentage of AUCtz-infinity of Metformin, where percentage is the unit of measurement.
Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Metformin: Tmax
Median of tmax of metformin
Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Metformin: λz (Terminal Elimination Rate Constant in Plasma)
Geometric mean of λz of metformin
Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Metformin: t1/2 (Terminal Half-life of the Analyte in Plasma)
Geometric mean of t1/2 of metformin
Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Metformin: MRTpo (Mean Residence Time of the Analyte in the Body After Peroral Administration)
Geometric mean of MRTpo of metformin
Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Metformin: CL/F
Geometric mean of CL/F of metformin
Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Metformin: Vz/F
Geometric mean of Vz/F of metformin
Time frame: Day 1 to 35 for period 1, and Day 36 to 70 for period 2
Electrocardiogram (ECG), Vital Signs, Physical Finding or Laboratory Finding Abnormalities
12-lead-Electrocardiogram (ECG), vital sign (blood pressure and pulse rate), physical finding and laboratory abnormalities
Time frame: Day 1 to 4 for period 1, and day 36 to 39 for period 2
Participants With Treatment Emergent Adverse Events
Number of patients with treatment emergent AEs
Time frame: Day 1 to 4 for period 1, and day 36 to 39 for period 2
Participants Who Discontinued the Trial Because of an Adverse Event
Number of participants who discontinued the trial because of an adverse event
Time frame: Day 1 to 4 for period 1, and day 36 to 39 for period 2
Assessment of Tolerability by the Investigator
Qualitative variable assessing the tolerability by the investigator
Time frame: Day 1 to 4 for period 1, and day 36 to 39 for period 2
| Milestone | Standard Batch Then Side Batch | Side Batch Then Standard Batch |
|---|---|---|
| Started | 20 | 20 |
| Completed | 20 | 20 |
| Not completed | 0 | 0 |
| Milestone | Standard Batch Then Side Batch | Side Batch Then Standard Batch |
|---|---|---|
| Started | 20 | 20 |
| Completed | 20 | 20 |
| Not completed | 0 | 0 |
| Milestone | Standard Batch Then Side Batch | Side Batch Then Standard Batch |
|---|---|---|
| Started | 20 | 20 |
| Completed | 20 | 20 |
| Not completed | 0 | 0 |
Geometric mean of Cmax of Linagliptin
| nmol/L | Standard Batch | Side Batch |
|---|---|---|
| Linagliptin: Maximum Measured Concentration (Cmax) | 5.36 ± 20.3 | 5.39 ± 20.3 |
Geometric mean of AUC0-72 of Linagliptin
| nmol*hr/L | Standard Batch | Side Batch |
|---|---|---|
| Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72) | 179 ± 21.6 | 179 ± 20.5 |
Geometric mean of AUC0-infinity of Linagliptin
| nmol*hr/L | Standard Batch | Side Batch |
|---|---|---|
| Linagliptin: AUC0-infinity | 267 ± 25.4 | 267 ± 23.6 |
Geometric Mean of percentage of AUCtz-∞ of linagliptin, where percentage is the unit of measurement.
| percentage | Standard Batch | Side Batch |
|---|---|---|
| Linagliptin: Percentage of AUCtz-∞ Obtained by Extrapolation | 32.6 ± 17.5 | 32.1 ± 20.3 |
Median of the t_max of linagliptin
| hr | Standard Batch | Side Batch |
|---|---|---|
| Linagliptin: Time to Maximum Measured Concentration of the Analyte in Plasma (Tmax) | 3.00 (0.667 to 6.02) | 3.00 (0.983 to 6.02) |
Geometric mean of the λ_z of linagliptin
| 1/hr | Standard Batch | Side Batch |
|---|---|---|
| Linagliptin: λz (Terminal Elimination Rate Constant in Plasma) | 0.0153 ± 17.1 | 0.0152 ± 21.6 |
Geometric mean of the t1/2 of linagliptin
| hr | Standard Batch | Side Batch |
|---|---|---|
| t1/2 (Terminal Half-life of the Analyte in Plasma) | 45.4 ± 17.1 | 45.6 ± 21.6 |
Geometric mean of the MRTpo of linagliptin
| hr | Standard Batch | Side Batch |
|---|---|---|
| Linagliptin: MRTpo (Mean Residence Time of the Analyte in the Body After Peroral Administration) | 64.6 ± 15.7 | 64.5 ± 19.5 |
Geometric mean of the CL/F of linagliptin
| mL/min | Standard Batch | Side Batch |
|---|---|---|
| Linagliptin: Apparent Clearance of the Analyte in Plasma After Extravascular Administration (CL/F) | 330 ± 25.4 | 330 ± 23.6 |
Geometric mean of the Vz/F of linagliptin
| Liter | Standard Batch | Side Batch |
|---|---|---|
| Linagliptin: Apparent Volume of Distribution During the Terminal Phase Following an Extravascular Dose (Vz/F) | 1300 ± 22.8 | 1300 ± 24.6 |
Geometric Mean of Cmax of Metformin
| ng/mL | Standard Batch | Side Batch |
|---|---|---|
| Metformin: Cmax | 1790 ± 23.0 | 1820 ± 25.5 |
Geometric Mean of AUC0-tz of Metformin
| ng*hr/mL | Standard Batch | Side Batch |
|---|---|---|
| Metformin: AUC0-tz | 12100 ± 21.4 | 12100 ± 19.4 |
Geometric Mean of AUC0-infinity of Metformin
| ng*h/mL | Standard Batch | Side Batch |
|---|---|---|
| Metformin: AUC0-infinity | 12400 ± 21.2 | 12300 ± 19.9 |
Geometric Mean of the percentage of AUCtz-infinity of Metformin, where percentage is the unit of measurement.
| percentage | Standard Batch | Side Batch |
|---|---|---|
| Metformin: Percentage of AUCtz-∞ Obtained by Extrapolation | 1.51 ± 87.4 | 1.52 ± 97.0 |
Median of tmax of metformin
| hr | Standard Batch | Side Batch |
|---|---|---|
| Metformin: Tmax | 1.99 (0.667 to 4.02) | 2.00 (0.65 to 4.02) |
Geometric mean of λz of metformin
| 1/hr | Standard Batch | Side Batch |
|---|---|---|
| Metformin: λz (Terminal Elimination Rate Constant in Plasma) | 0.0493 ± 71.0 | 0.0514 ± 84.3 |
Geometric mean of t1/2 of metformin
| hr | Standard Batch | Side Batch |
|---|---|---|
| Metformin: t1/2 (Terminal Half-life of the Analyte in Plasma) | 14.1 ± 71.0 | 13.5 ± 84.3 |
Geometric mean of MRTpo of metformin
| hr | Standard Batch | Side Batch |
|---|---|---|
| Metformin: MRTpo (Mean Residence Time of the Analyte in the Body After Peroral Administration) | 8.27 ± 31.1 | 8.23 ± 36.9 |
Geometric mean of CL/F of metformin
| mL/min | Standard Batch | Side Batch |
|---|---|---|
| Metformin: CL/F | 1350 ± 21.2 | 1350 ± 19.9 |
Geometric mean of Vz/F of metformin
| Liter | Standard Batch | Side Batch |
|---|---|---|
| Metformin: Vz/F | 1640 ± 74.3 | 1580 ± 82.4 |
12-lead-Electrocardiogram (ECG), vital sign (blood pressure and pulse rate), physical finding and laboratory abnormalities
| Participants | Standard Batch | Side Batch |
|---|---|---|
| Physical examination abnormalities | 0 | 0 |
| Vital sign abnormalities | 0 | 0 |
| ECG abnormalities | 0 | 0 |
| Laboratory finding abnormalities | 0 | 0 |
Number of patients with treatment emergent AEs
| Participants | Standard Batch | Side Batch |
|---|---|---|
| Headache | 6 | 9 |
| Nausea | 0 | 1 |
| Vomiting | 2 | 1 |
| Fatigue | 1 | 0 |
Number of participants who discontinued the trial because of an adverse event
| Participants | Standard Batch | Side Batch |
|---|---|---|
| Participants Who Discontinued the Trial Because of an Adverse Event | 0 | 0 |
Qualitative variable assessing the tolerability by the investigator
| Participants | Standard Batch | Side Batch |
|---|---|---|
| Good | 39 | 40 |
| Not satisfactory | 1 | 0 |
Collected over 4 days (period 1) + 4 days (treatment period 2). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Standard Batch | — | 0/40 (0%) | 7/40 (17.5%) |
| Side Batch | — | 0/40 (0%) | 11/40 (27.5%) |
| Event | Standard Batch | Side Batch |
|---|---|---|
| HeadacheNervous system disorders | 7/40 | 11/40 |
| Age, Continuous(Years) | All Participants |
|---|---|
| Mean | 36.8 ± 6.8 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 20 |
| Male | 20 |
| Body mass index(kg/m^2) | All Participants |
|---|---|
| Mean | 23.74 ± 2.74 |
The record gives a start of Sep 2010 and a primary completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Linagliptin · Metformin